Delivery Order SPE2DB20D1004-SPE2DB25FNHVX
Award Date 6/18/25
Potential Completion Date 6/20/25
Potential Value $4.9K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,746.28 for DUPIXENT 200 mg/1.14 mL pen injectables on May 30, 2025, with completion scheduled for June 2, 2025. This competitively awarded, firm fixed-price contract involves no set-aside provisions and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $6,819.43 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 200 MG/1.14 ML pen injectors on August 6, 2025, with completion expected by August 7, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a prescription biologic medication used to treat various...
- The Defense Logistics Agency awarded a $39,444.01 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pens on September 8, 2025, with an ultimate completion date of September 9, 2025. DUPIXENT (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic rhinosinusitis. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $15,645.39 to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen injectors on September 5, 2025, with completion targeted for September 8, 2025. This competitively awarded, firm fixed-price delivery order represents a pharmaceutical supply requirement under AmerisourceBergen's broader relationship with the federal government. DUPIXENT (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $26,202.83. The contract, awarded on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing DLA contract vehicle. DUPIXENT (dupilumab) is a prescription biologic medication used to treat moderate-to-severe atopic...
- The Defense Logistics Agency awarded a delivery order valued at $4,697.47 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 MG/2 ML pen injectors on August 26, 2025, with an ultimate completion date of August 27, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a prescription biologic medication used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $12,879.52 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen auto-injectors on August 8, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a $24,542.35 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of DUPIXENT 300 mg/2 mL pens (2 mL units). This is a firm fixed-price, non-set-aside contract with a completion date of July 23, 2025, and performance at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a biologic immunosuppressant used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and other allergic...
- The Defense Logistics Agency awarded a $18,121.68 delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of DUPIXENT 300 mg/2 ml pen injectable medication in 2 ml quantities. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 14, 2025. The contract is being performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, and represents a child delivery order under the...
- The Defense Logistics Agency awarded a delivery order valued at $14,097.56 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 ml pen injectors on August 14, 2025, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a biologic immunosuppressant medication used to treat...